News|Videos|September 15, 2026

Inside FIND-CKD: The Data Behind the Trial's 23% Risk Reduction

Author(s)Brendon Neuen, MBBS, PhD, Shikha Wadhwani, MD, MS

Brendan Neuen breaks down the full FIND-CKD primary and secondary endpoint data, subgroup consistency, and safety signals.

This is a deep dive into one segment of a recent episode of Kidney Compass: Navigating Clinical Trials, HCPLive's podcast co-hosted by Shikha Wadhwani, MD, and Brendan Neuen, MBBS, PhD. In this episode, Neuen steps out of his usual co-host role to join as a guest, discussing the FIND-CKD trial results he presented at ERA. The full episode also covers the glomerulonephritis subgroup analysis and pooled safety data.

Related to this article

November 3rd, 2026

8 Nephrology Headlines You Missed in October 2026

Nephrology in October 2026: FDA approves ravulizumab for IgAN, plus ORIGIN 3, RAINIER, TELIGAN, and ATTACK data from Kidney Week.

October 30th, 2026

ASN Kidney Week 2026 Recap: 8 Key Updates in Kidney Disease to Know

IgAN late-breakers led the meeting, alongside new data on aspirin, dialysis access, donor pregnancy, potassium, and depression.

Pegcetacoplan Maintains C3G Response at 76 Weeks, With Carla Nester, MD

November 5th, 2026

Biopsy Scarring and Pegcetacoplan Response in C3G, With Carla Nester, MD

Carla Nester, MD, discusses sustained proteinuria reduction and kidney function findings through 76 weeks of pegcetacoplan treatment.

November 6th, 2026

Saroglitazar Resolves MASH Without Fibrosis Worsening: EVIDENCES X

In the phase 2b EVIDENCES X trial, saroglitazar 4 mg resolved MASH without worsening fibrosis in 39.1% of patients vs 13.7% with placebo at 52 weeks.

November 6th, 2026

Q&A: Discussing 2027 GOLD Report Updates in COPD, With David Singh, MD

Dave Singh, MD, reflects on 2027 GOLD report refinements, from mucus plugs and early COPD to biologics awaiting regulatory approval.

November 6th, 2026

Semaglutide Linked to Lower Liver Enzymes, Weight in Real-World MASH Data

Retrospective data show semaglutide 2.4 mg was linked to lower liver enzymes, weight, and HbA1c in MASH, including vs resmetirom in a real-world cohort.

November 6th, 2026

Q&A: Why IL-33 Matters for Mucus Plugs, Inflammation in COPD

Francesca Polverino, MD, PhD, explains how oxidized and reduced IL-33 drive mucus dysfunction and inflammation in COPD, and why mucus plugs matter.

November 6th, 2026

Triple Therapy More Than Doubles HBsAg Loss vs Peginterferon in HBV

Phase 2 ENHANCE and ENRICH data show BRII-179 plus elebsiran and peginterferon increased HBsAg loss in chronic HBV, with priming halving peginterferon use.